Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 576-583

  Tseng, Leon F ^a   Narita, Minoru ^a   Suganuma, Chiaki ^a   Mizoguchi, Hirokazu ^a   Ohsawa, Masahiro ^c   Nagase, Hiroshi ^b   Kampine, John P ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b TORAY INDUSTRIES INC   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR ANTAGONIST; ENDOMORPHIN 1; ENDOMORPHIN 2; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALTREXAMINE DERIVATIVE; NALTRIBEN; NORBINALTORPHIMINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HOT PLATE TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; IMMUNE SERA; INJECTIONS, INTRAVENTRICULAR; LIGANDS; MALE; MICE; MICE, INBRED ICR; OLIGOPEPTIDES; PAIN MEASUREMENT; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 0033974184     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bodnar RJ, Krzanowska E, Leventhal L, Rossi GC, Mathis JP and Pasternak GW (1997) Pharmacological characterization of endomorphin-I and endomorphin-II analgesia and gastrointestinal transit in mice. Soc Neurosci Abstr 23:680.
2. Bradbury AF, Smyth DF, Snell CR, Birdsall NJM and Hulme EC (1976) C-fragment of lipotropin has a high affinity for brain opiate receptors. Nature (Lond) 260:793-795.
3. Corbett AD, Paterson SJ and Kosterlitz HW (1993) Selectivity of ligands for opioid receptors, in Opioids I (Handbook of Experimental Pharmacology) (Herz A ed) vol 104/I, pp 645-679, Springer-Verlag, New York.
4. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
5. Eddy NB and Leimbach D (1953) Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Ther 107:385-393.
6. Endoh T, Matsuura H, Tanaka C and Nagase H (1992) Nor-binaltorphimine: A potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn 316:30-42.
7. Goldberg IE, Rosi GC, Letchworth SR, Mathis JP, Ryan-Moro J, Leventhal L, Su W, Emmel D, Bolan EA and Pasternak GW (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286:1007-1013.
8. Goldstein A, Fischli W, Lowney LI, Hunkapiller M and Hood L (1981) Porcine pituitary dynorphin: Complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad Sci USA 78:7219-7223.
9. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M and Hood L (1979) Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 78:6666-6670.
10. Haley TJ and McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol 12:12-15.
11. Höllt V, Przewlocki R and Herz A (1978) Radioimmunoassay of β-endorphin basal and stimulated levels in extracted rat plasma. Naunyn-Schmiederg's Arch Pharmacol 303:171-174.
12. Horan P, Taylor J, Yamamura HI and Porreca F (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 260:1237-1243.
13. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA and Morris HR (1975) Identification of two related pentapeptidess from the brain with potent opiate agonist activity. Nature (Lond) 258:577-580.
14. Knapp RJ, Vaughn LK and Yamamura HI (1995) Selective lignads for μ and δ opioid receptors, in The Pharmacology of Opioid Peptides (Tseng LF ed) pp 1-28, Harwood Academic Publishers, Chur, Switzerland.
15. Li CH and Chung D (1976) Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands. Proc Natl Acad Sci USA 73:1145-1148.
16. Martin-Schild S, Gerall AA, Kastin AJ and Zadina JE (1999) Differential distribution of endomorphin 1-and endomorphin 2-like immunoreactivities in the CNS of the rodent. J Comp Neurol 405:450-471.
17. Martin-Schild S, Gerall AA, Kastin AJ and Zadina JE (1998) Endomorphin-2 is an endogenous opioid in the primary sensory afferent fibers. Peptides 19:1783-1789.
18. Martin-Schild S, Zadina JE, Gerall AA, Vigh S and Kastin AJ (1997) Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord. Peptides 18:1641-1649.
19. Mizoguchi H, Narita M, Nagase H and Tseng LF (1995) Antisense oligodeoxynucleotide to a δ-opioid receptor blocks the antinociception induced by cold water swimming. Regul Pept 59:255-259.
20. Narita M and Tseng LF (1998) Evidence for the exitence of β-endorphin-sensitive "e-opioid receptor" in the brain: The mechanisms of ∈-mediated antinociception. Jpn J Pharmacol 76:233-2531,
21. Nock B (1995) κ and ∈ opioid receptor binding, in The Pharmacology of Opioid Peptides (Tseng LF ed) pp 29-56, Harwood Academic Publishers, Chur, Switzerland.
22. Pierce TL, Grahek MD and Wessendorf MW (1998) Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. Neuroreport 9:385-389.
23. Portoghese PS (1991) An approach to the design of receptor-type selective non-peptide antagonists of peptidergic receptors; δ opioid antagonists. J Med Chem 34:1757-1762.
24. 1-opioid receptor antagonists: 7-Benzylididene naltrexamine. Eur J Pharmacol 218:195-196.
25. Reisine T (1995) Review: Neurotransmitter receptors: V, Opiate receptors. Neuropharmacology 34:463-472.
26. Schreff M, Schulz S, Wiborny D and Höllt V (1998) Immunofluorescent identification of endomorphin-2-contraining nerve fibers and terminais in the rat brain and spinal cord. Neuroreport 9:1031-1034.
27. Shane R, Wilk S and Bodnar RJ (1999) Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 815:278-286.
28. Spanagel R, Almeida OFX and Shippenberg TS (1994) Evidence that norbinaltorphimine can function as an antagonist at multiple opioid receptor subtypes. Eur J Pharmacol 264:157-162, 1994.
29. Stone LS, Fairbanks CA, Laughlin TM, Nguyen HO, Bushy TM, Wessendorf MW and Wilcox GL (1997) Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8:3131-3135.
30. Takemori AE, Larson DL. and Portoghese PS (1981) The irreversible narcotic antagonistic properties of the fumarate methylester derivative of naltrexone. Eur J Pharmacol 70:445-451.
31. Tallarida RJ and Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York.
32. Tseng LF (1995) Mechanisms of β-endorphin-induced antinociception, in The Pharmacology of Opioid Peptides (Tseng LF ed) pp 249-269, Harwood Academic Publishers, Chur, Switzerland.
33. Tseng LF and Collins KA (1993) Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly ad-ministered bremazocine but not morphine in the mouse. J Pharmacol Exp Ther 266:1430-1438.
34. Tseng LF, Suganuma C, Narita M, Oji GS, Tseng EL, Bhaita A, Mizoguchi H and Nagase H (1998) Differential mechanism mediating antinociception induced by supraspinally administered newly discovered endogenous opioid peptides endomorphin-1 and endomorphin-2 in the mouse. Soc Neurosci Abstr 24:1356.
35. Xu JY and Tseng LF (1997) [Met]enkephalin in the spinal cord is involved in the antinociception induced by intracerebroventricularly-administrered etorphine in the mouse. Neurosci 80:579-585.
36. Zadina JE, Hackler L, Ge L-J and Kastin AJ (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature (Lond) 386:499-502.